Last reviewed · How we verify
EC5026 oral tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
EC5026 oral tablet (EC5026 oral tablet) — EicOsis Human Health Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| EC5026 oral tablet TARGET | EC5026 oral tablet | EicOsis Human Health Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- EC5026 oral tablet CI watch — RSS
- EC5026 oral tablet CI watch — Atom
- EC5026 oral tablet CI watch — JSON
- EC5026 oral tablet alone — RSS
Cite this brief
Drug Landscape (2026). EC5026 oral tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ec5026-oral-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing